文献速递神经肿瘤

低级别胶质瘤多药联合与单药化疗作为多模式治疗组成部分的诊疗模式与结局

Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma.
PubMed 文献 · J Neurooncol · 2017-04-21

基于美国国家癌症数据库(NCDB),纳入1029例接受根治性放疗联合化疗的高危II级低级别胶质瘤患者,其中989例(96.1%)接受单药化疗(SAC,类似替莫唑胺),40例(3.9%)接受多药化疗(MAC,类似PCV)。两组中位总生存期(OS)无差异(45.3个月 vs 59.2个月,p=0.861),多因素分析中化疗方案对OS无影响(p=0.804)。

要点

  • 高危II级低级别胶质瘤中,单药化疗使用率(96.1%)远高于多药化疗(3.9%)。
  • 单药与多药化疗组中位OS无差异(45.3个月 vs 59.2个月,p=0.861)。
  • 多因素分析中,用单药替代多药化疗对OS无影响(p=0.804)。

核心结论

  • 美国高危低级别胶质瘤患者中单药化疗使用显著多于多药化疗,两组总生存期无差异,多因素分析中化疗方案不影响OS,提示以单药替代多药化疗可能不损害结局。

研究设计与样本

  • 利用美国国家癌症数据库(NCDB)查询接受根治性放疗联合化疗的高危II级低级别胶质瘤患者,分为单药化疗(SAC)和多药化疗(MAC)两个队列。
  • 共纳入1029例患者,其中989例(96.1%)接受SAC,40例(3.9%)接受MAC。
  • 采用Kaplan-Meier分析比较总生存期(OS),Cox比例风险模型确定与OS独立相关的变量。

主要发现

  • 近期(2010-2012年)治疗的患者接受MAC的可能性更低(p=0.029)。
  • MAC组与SAC组的中位OS无差异(45.3个月 vs 59.2个月,p=0.861)。
  • OS更差的独立预测因素包括年龄>40岁、高Charlson-Deyo指数、其他政府/未记录保险状态、仅活检、星形细胞瘤组织学、西部地理区域和较高收入。
  • 以SAC替代MAC对OS无影响(p=0.804)。

临床怎么用

  • 原文结论提示,在高危低级别胶质瘤的多模式治疗中,以单药化疗替代多药化疗可能不会对结局产生不利影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For high-risk low-grade gliomas (LGGs), adjuvant radiotherapy (RT) with procarbazine/lomustine/vincristine (PCV) chemotherapy increases overall survival (OS) over RT alone. However, in practice, temozolomide (TMZ) is often used instead of PCV. Using the National Cancer Data Base (NCDB), we provide the first investigation of practice patterns and outcomes of chemoradiotherapy with single-agent chemotherapy (SAC, analogous to TMZ) or multi-agent chemotherapy (MAC, analogous to PCV) for LGG. Patients with high-risk Grade II LGGs were queried in the NCDB. Inclusion was limited to patients treated with definitive RT and chemotherapy. Patients were divided into cohorts receiving SAC or MAC. Kaplan-Meier analysis compared overall survival (OS), and Cox proportional hazards models determined variables independently associated with OS. Of 1029 patients, 989 (96.1%) received SAC, while 40 (3.9%) received MAC. Patients treated more recently (2010-2012) were less likely to receive MAC (p = 0.029). No differences in median OS were observed between patients treated with MAC and SAC (45.3 vs. 59.2 months, p = 0.861). Independent predictors of worse OS included age >40, high Charlson-Deyo index, other governmental/unrecorded insurance status, biopsy only, astrocytoma histology, Western geographical region, and higher income. Substuting MAC with SAC had no impact on OS (p = 0.804). There is a significantly greater utilization of SAC compared to MAC in the US. There were no differences in OS between patients receiving SAC and MAC, nor did this factor impact OS on multivariate analysis, suggesting that the practice of substituting MAC with SAC for management of LGG may not adversely affect outcome.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Haque W, Verma V, Butler EB, et al. Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma. J Neurooncol. 2017. PMID: 28432588. doi:10.1007/s11060-017-2443-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。